Applying AI to All Stages of Drug Discovery and Development - The Impact on Patients' Lives

Originally Aired July 27, 2022

A Discussion on the Human Impact of AI/ML in Cancer Research

With the exploding availability of omics data, the pharmaceutical industry has significantly increased investment in AI/ML technology to extract information to guide all aspects of R&D, from target identification, patient selection, and stratification to real-world evidence generation. When correctly applied, these investments result in not only accelerating business but also directly impacting human life. Sylvie Laquerre from Johnson & Johnson R&D (Janssen Pharmaceuticals) will discuss how AI/ML has helped her team to make a positive impact on peoples' lives.

What's in it for you?

Investment in Data Science

Learn why pharmaceutical companies are investing in data science as a top priority.

Impact on Cancer Research

See how these investments are making a significant impact on cancer research.

Impact on Patient Prognosis

Explore what this means for patients diagnosed with cancer and how this progress may shape treatment strategies.

Meet the speakers

Sylvie Laquerre

VP, Solid Tumor Targeted Therapy Disease Area Stronghold Lead, Oncology TA, Janssen Research & Development, LLC

Sylvie Laquerre, Ph.D. is Vice President, Solid Tumor Targeted Therapy (ST3) Disease Area Stronghold (DAS), Oncology Therapeutic Area, Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. In this role, Dr. Laquerre is responsible for the strategic direction and execution of the ST3 DAS portfolio from early drug discovery efforts through clinical development. During her tenure at Janssen, Dr. Laquerre advanced strong discovery and translational research to deliver a robust preclinical and clinical pipeline of novel targeted agents and immuno-stimulatory biologics. She contributed to discovery, development and approval of Balversa (FGFR inhibitor) and Rybrevant (Bispecific EGFR/cMET antibody). Under her supervision additional inhibitors and biologics have been discovered and are now under clinical development. Dr. Laquerre also contributed to multiple key collaborations and acquisitions to enhance the Janssen’s R&D portfolio.

Caroline Phares

Senior Director, Health and Life Sciences, Domino Data Lab

Caroline Phares leads the Health and Life Sciences strategy for Domino Data Lab. Prior to Domino, she enjoyed 20 years of success at GSK as a business partner and technology leader in designing, delivering, and supporting innovative solutions across R&D. During her time at GSK, she was involved in collaborative efforts with other large pharmaceutical companies and has influenced industry trends in technology solutions to common problems and use cases. She is driven to pursue and implement positive, transformational change through scientific and technological progress, and enjoys applying modern tools and methodologies to problems which may have once seemed unsolvable.

Streamline R&D with a single analytics and AI/ML platform

Explore related resources


Unleashing Exceptional Performance

Najat Khan (Janssen), and Thomas Robinson (Domino), discuss Johnson & Johnson, scaling data science, and the tech that makes it possible.

Watch now


Digital Transformation Demands a Flexible SCE

Deploying a new, modern statistical computing environment (SCE) enables R&D organizations to accelerate and make optimal use of their data.

Read now


Domino for Life Sciences

Take advantage of the latest data science and statistical techniques on the only platform that can unite your processes for research and clinical studies.

Learn more